Salirasib
Salirasib Basic information
- Product Name:
- Salirasib
- Synonyms:
-
- 2-(((2E,6E)-3,7,11-Trimethyldodeca-2,6,10-trien-1-yl)thio)benzoicacid
- CS-1744
- Salirasib(S-Farnesylthiosalicylic aci)
- FARNESYLTHIOSALICYLIC ACID
- FTS
- Unii-mzh0om550m
- (3,7,11-TRIMETHYLDODECA-2,6,10-TRIENYL)-2-THIOBENZOIC ACID
- 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic acid
- CAS:
- 162520-00-5
- MF:
- C22H30O2S
- MW:
- 358.54
- Product Categories:
-
- Aromatics
- Inhibitors
- Intermediates & Fine Chemicals
- Pharmaceuticals
- Sulfur & Selenium Compounds
- API
- Mol File:
- 162520-00-5.mol
Salirasib Chemical Properties
- Melting point:
- 64-66°C
- Boiling point:
- 486.0±45.0 °C(Predicted)
- Density
- 1.05
- storage temp.
- -20°C
- solubility
- DMSO: soluble20mg/mL, clear
- pka
- 3.50±0.36(Predicted)
- form
- powder
- color
- white to beige
- Stability:
- Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
- InChI
- InChI=1S/C22H30O2S/c1-17(2)9-7-10-18(3)11-8-12-19(4)15-16-25-21-14-6-5-13-20(21)22(23)24/h5-6,9,11,13-15H,7-8,10,12,16H2,1-4H3,(H,23,24)/b18-11+,19-15+
- InChIKey
- WUILNKCFCLNXOK-CFBAGHHKSA-N
- SMILES
- C(O)(=O)C1=CC=CC=C1SC/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/C
Salirasib Usage And Synthesis
Description
Association of Ras protein with the inner surface of the plasma membrane is required for Ras signaling activity. Farnesyl thiosalicylic acid (FTS) is an inhibitor of Ras-
Chemical Properties
Pale Yellow Solid
Uses
It is a new specific nontoxic drug with a mild hydrophobic nature, which acts as a Ras antagonist and can therefore be used for stent applications as well as for local cancer treatment.
Uses
Salirasib has been used as a farnesyltransferase inhibitor.
Uses
Salirasib is a new specific nontoxic drug with a mild hydrophobic nature, which acts as a Ras antagonist and can therefore be used for stent applications as well as for local cancer treatment.
Definition
ChEBI: Salirasib is a sesquiterpenoid.
Biochem/physiol Actions
Salirasib (Farnesylthiosalicylic acid) is a RAS inhibitor that acts by dislodging the farnesylated protein from the membrane, facilitating Ras degradation. Salirasib impairs downstream signaling and suppresses growth and migration of proliferating tumor cells in in vitro and in vivo models. Salirasib (Farnesylthiosalicylic acid) has recently been shown to possess significant anti-inflammatory and anti-arthritic properties.
References
[1] DANIELLA MARCIANO. Farnesyl Derivatives of Rigid Carboxylic Acids - Inhibitors of ras-Dependent Cell Growth[J]. Journal of Medicinal Chemistry, 1995, 38 8: 1267-1272. DOI:10.1021/jm00008a004
[2] Selective inhibition of Ras-dependent cell growth by farnesylthiosalicylic acid (salirasib) in patients with solid tumors
[3] RONI HAKLAI. Dislodgment and Accelerated Degradation of Ras†[J]. Biochemistry Biochemistry, 1998, 37 5: 1306-1314. DOI:10.1021/bi972032d
[4] DANIEL LAHERU. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.[J]. Investigational New Drugs, 2012: 2391-2399. DOI:10.1007/s10637-012-9818-6
[5] APOSTOLIA MARIA TSIMBERIDOU. Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.[J]. Cancer Chemotherapy and Pharmacology, 2010, 65 2: 235-241. DOI:10.1007/s00280-009-1027-4
[6] N CHARETTE. Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms[J]. Cell Death & Disease, 2013, 4 1: e471-e471. DOI:10.1038/cddis.2012.200
[7] MICHAEL MAHER. Activation of TRPA1 by farnesyl thiosalicylic acid.[J]. Molecular Pharmacology, 2008, 73 4: 1225-1234. DOI:10.1124/mol.107.042663
SalirasibSupplier
- Tel
- 15076683720
- klq@cw-bio.com
- Tel
- sales@boylechem.com
- Tel
- 18210857532; 18210857532
- jkinfo@jkchemical.com
- Tel
- 821-50328103-801 18930552037
- 3bsc@sina.com
- Tel
- +86-21-20908456
- sales@BioChemBest.com
Salirasib(162520-00-5)Related Product Information
- TYRPHOSTIN AG 1296
- Imatinib mesylate
- AG 490
- (E)-3-[[[3-[2-(7-CHLORO-2-QUINOLINYL)ETHENYL]PHENYL]-[[(3-DIMETHYLAMINO)-3-OXOPROPYL]THIO]METHYL]THIO]-PROPANOIC ACID, SODIUM SALT
- Gefitinib
- U0126-EtOH
- SB 202190
- ABT 737
- Crizotinib
- Rapamycin
- Thiobenzoic acid
- Salirasib
- (E)-3,7-Dimethylocta-2,6-diene-1-thiol
- (3-METHYL-BUT-2-ENYLSULFANYL)-BENZENE